Free Trial
NASDAQ:SYBX

Synlogic (SYBX) Stock Price, News & Analysis

Synlogic logo
$1.10 0.00 (0.00%)
As of 10/8/2026 12:08 PM Eastern

About Synlogic Stock (NASDAQ:SYBX)

Advanced

Key Stats

Today's Range
$1.10
▼
$1.10
50-Day Range
$1.07
▼
$1.23
52-Week Range
$0.54
▼
$1.87
Volume
73,886 shs
Average Volume
68,078 shs
Market Capitalization
$13.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Synlogic, Inc. was a clinical-stage biotechnology company focused on developing medicines based on synthetic biology. The company engineered probiotic bacteria, referred to as Synthetic Biotics, to perform specific therapeutic functions inside the gastrointestinal tract, such as metabolizing disease-associated compounds or producing beneficial molecules.

Its development programs targeted rare metabolic disorders, including phenylketonuria (PKU) and homocystinuria. Among its investigational candidates were SYNB1934 and the earlier SYNB1618 for PKU, as well as SYNB1353 for homocystinuria. These programs were designed to address underlying metabolic imbalances by using engineered bacteria to break down or process substances that patients are unable to metabolize adequately.

Synlogic was founded in 2013 and was headquartered in Cambridge, Massachusetts. The company conducted preclinical and clinical research primarily in the United States and had no commercially marketed products; its activities centered on research, development and clinical evaluation of Synthetic Biotic medicines. The company later undertook strategic changes to its pipeline and operations, and information about its ongoing corporate activities and leadership may vary from earlier public filings.

AI Generated. May Contain Errors.

Receive SYBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYBX Stock News Headlines

No. 1 stock to cash in on the death of iPhone
Analyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.tc pixel
Synlogic Challenges Nasdaq Delisting Notice
We Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business Growth
See More Headlines

SYBX Stock Analysis - Frequently Asked Questions

Synlogic's stock was trading at $1.12 at the beginning of the year. Since then, SYBX shares have decreased by 1.8% and is now trading at $1.10.

Synlogic, Inc. (NASDAQ:SYBX) issued its quarterly earnings data on Thursday, November, 13th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.08.

Shares of Synlogic reverse split on Thursday, September 28th 2023.The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Synlogic (SYBX) raised $88 million in an initial public offering on Wednesday, September 30th 2015. The company issued 6,250,000 shares at $13.00-$15.00 per share.

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synlogic investors own include Sangamo Therapeutics (SGMO), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE) and Exelixis (EXEL).

Company Calendar

Last Earnings
11/13/2025
Today
10/09/2026
Next Earnings (Estimated)
11/11/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SYBX
CIK
1527599
Employees
80
Year Founded
2013

Profitability

EPS (Trailing Twelve Months)
($0.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$23.36 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.47%
Return on Assets
-18.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.65
Quick Ratio
2.65

Sales & Book Value

Annual Sales
$8 thousand
Price / Sales
1,684.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.09 per share
Price / Book
1.01

Miscellaneous

Outstanding Shares
12,249,000
Free Float
11,392,000
Market Cap
$13.47 million
Optionable
No Data
Beta
0.61

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:SYBX) was last updated on 10/10/2026 by MarketBeat.com Staff.
From Our Partners